These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 29382647)

  • 1. Optimizing Amplification of the GC-Rich
    Colebatch AJ; Witkowski T; Waring PM; McArthur GA; Wong SQ; Dobrovic A
    Clin Chem; 2018 Apr; 64(4):745-747. PubMed ID: 29382647
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnostic utility of droplet digital PCR to detect TERT promoter mutations among glioblastoma samples using 7-deaza-dGTP.
    Abarna R; Nancy R; Chacko A; Chacko G; Pai R
    J Clin Pathol; 2022 Feb; 75(2):140-142. PubMed ID: 33766956
    [No Abstract]   [Full Text] [Related]  

  • 3. Betaine, dimethyl sulfoxide, and 7-deaza-dGTP, a powerful mixture for amplification of GC-rich DNA sequences.
    Musso M; Bocciardi R; Parodi S; Ravazzolo R; Ceccherini I
    J Mol Diagn; 2006 Nov; 8(5):544-50. PubMed ID: 17065422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Novel Mutation-Specific Droplet Digital PCR Assays Detecting TERT Promoter Mutations in Tumor and Plasma Samples.
    Corless BC; Chang GA; Cooper S; Syeda MM; Shao Y; Osman I; Karlin-Neumann G; Polsky D
    J Mol Diagn; 2019 Mar; 21(2):274-285. PubMed ID: 30827467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporation of dITP or 7-deaza dGTP during PCR improves sequencing of the product.
    Dierick H; Stul M; De Kelver W; Marynen P; Cassiman JJ
    Nucleic Acids Res; 1993 Sep; 21(18):4427-8. PubMed ID: 8415021
    [No Abstract]   [Full Text] [Related]  

  • 6. The Sensitive Detection of Telomerase Reverse Transcriptase Promoter Mutation by Amplification Refractory Mutation System-PCR.
    Liu J; Zhao Z; Sun M; Chen K; Yuan W; Jiang G
    Genet Test Mol Biomarkers; 2016 Feb; 20(2):90-3. PubMed ID: 26741813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of of L-2'-deoxyguanosine 5'-triphosphate (L-dGTP) and L-2'-deoxythymidine 5'-triphosphate (L-dTTP) on human telomerase.
    Yamaguchi T; Yamada R; Shudo K; Saito M; Ishikawa F; Saneyoshi M
    Nucleic Acids Symp Ser; 1999; (42):205-6. PubMed ID: 10780451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Qualitative and quantitative detection of methylation at CpG sites using the fluorescein-dGTP incorporated asymmetric PCR assay strategy.
    Hong T; Wang T; He Z; Ma J; Xiao H; Huang J; Mao W; Zhou X
    Chem Commun (Camb); 2014 Jun; 50(50):6653-5. PubMed ID: 24823384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human telomerase inhibition by 7-deaza-2'-deoxypurine nucleoside triphosphates.
    Fletcher TM; Salazar M; Chen SF
    Biochemistry; 1996 Dec; 35(49):15611-7. PubMed ID: 8961922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
    Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
    Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M
    Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
    Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
    Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites.
    Cheng KA; Kurtis B; Babayeva S; Zhuge J; Tantchou I; Cai D; Lafaro RJ; Fallon JT; Zhong M
    Ann Diagn Pathol; 2015 Jun; 19(3):146-8. PubMed ID: 25862495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT promoter mutations in periocular carcinomas: implications of ultraviolet light in pathogenesis.
    Lin SY; Liao SL; Hong JB; Chu CY; Sheen YS; Jhuang JY; Tsai JH; Liau JY
    Br J Ophthalmol; 2016 Feb; 100(2):274-7. PubMed ID: 26472403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia.
    Papathomas TG; Oudijk L; Zwarthoff EC; Post E; Duijkers FA; van Noesel MM; Hofland LJ; Pollard PJ; Maher ER; Restuccia DF; Feelders RA; Franssen GJ; Timmers HJ; Sleijfer S; de Herder WW; de Krijger RR; Dinjens WN; Korpershoek E
    Endocr Relat Cancer; 2014 Aug; 21(4):653-61. PubMed ID: 24951106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
    Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful amplification of extremely GC-rich promoter regions using a novel 'slowdown PCR' technique.
    Bachmann HS; Siffert W; Frey UH
    Pharmacogenetics; 2003 Dec; 13(12):759-66. PubMed ID: 14646694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
    Cevik D; Yildiz G; Ozturk M
    World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
    Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
    Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
    Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
    Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.